1
|
The cardiovascular effects of GLP-1 receptor agonists.
|
Cardiovasc Ther
|
2010
|
1.12
|
2
|
PROactive: time for a critical appraisal.
|
Eur Heart J
|
2008
|
1.11
|
3
|
Applications of miRNA technology for atherosclerosis.
|
Curr Atheroscler Rep
|
2014
|
0.84
|
4
|
Matrix metalloproteinases: drug targets for myocardial infarction.
|
Curr Drug Targets
|
2013
|
0.84
|
5
|
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
|
Clin Ther
|
2003
|
0.84
|
6
|
Cardioprotection: the role of beta-blocker therapy.
|
J Clin Hypertens (Greenwich)
|
2005
|
0.84
|
7
|
Left ventricular remodeling: one small step for the extracellular matrix will translate to a giant leap for the myocardium.
|
Congest Heart Fail
|
2013
|
0.80
|
8
|
A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities.
|
J Clin Hypertens (Greenwich)
|
2013
|
0.79
|
9
|
Diabetic endovascular disease: role of coronary artery revascularization.
|
Am J Cardiol
|
2006
|
0.78
|
10
|
Is isolated systolic hypertension worse than combined systolic/diastolic hypertension?
|
J Clin Hypertens (Greenwich)
|
2012
|
0.78
|
11
|
Heart rate reduction: an old and novel candidate heart failure therapy.
|
Hypertension
|
2012
|
0.77
|
12
|
Tumor necrosis factor-alpha--converting enzyme roles in hypertension-induced hypertrophy: look both ways when crossing the street.
|
Hypertension
|
2009
|
0.75
|
13
|
Other important applications for beta-blockers in high-risk patients.
|
Postgrad Med
|
2003
|
0.75
|
14
|
Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations.
|
Postgrad Med
|
2011
|
0.75
|